论文部分内容阅读
目的 :进一步探索淋系分化抗原在急性髓性白血病 ( AML )中的表达特征及其对 AML患者预后的影响。方法 :采用间接免疫荧光法对 84例初诊 AML 患者进行了免疫表型检测 ,并用流式细胞仪对淋、髓两系分化抗原共表者做双标记分析。结果 :84例 AML 中 ,3 0例 ( 3 5 .72 % )有淋系抗原表达 ( ly+ )。对于双表型患者 ,流式细胞仪分析显示其白血病细胞表型不均一。在同等化疗强度基础上 ,ly+ 者较 ly- 者完全缓解 ( CR1 )率低 ,获 CR1 所需时间长 ,CR1 后无病生存期短 ( DFS期 ,P值匀 <0 .0 5 )。多因素分析表明 ly+是影响 AML 患者 DFS期的一个主要危险因素 ( P<0 .0 5 )。结论 :淋系分化抗原在 AML 中的表达具有复杂性 ,ly+的 AML 属于预后不良的临床亚型 ,应进一步探索针对性的治疗策略
Objective: To further explore the expression characteristics of lymphoid differentiation antigen in acute myeloid leukemia (AML) and its effect on the prognosis of AML patients. Methods: The immunophenotypes of 84 newly diagnosed AML patients were detected by indirect immunofluorescence. Double-labeled analysis was performed by flow cytometry. Results: In 84 cases of AML, 30 cases (35.72%) had lymphoid antigen expression (ly +). For patients with dual phenotype, flow cytometry analysis showed heterogeneous leukemia cell phenotypes. On the basis of the same chemotherapy intensity, patients with ly + had a lower rate of complete remission (CR1), longer duration of CR1, and no disease-free survival after CR1 (PFS, P <0.05). Multivariate analysis showed that ly + was a major risk factor for DFS in AML patients (P <0.05). CONCLUSION: The expression of lymphoid differentiation antigen in AML is complicated. Ly + AML belongs to the clinical subtype with poor prognosis, and the targeted treatment strategy should be further explored